Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110(6):1497–505. https://doi.org/10.1038/bjc.2014.80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noel A, Foidart JM, Birembaut P, Polette M, Gilles C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2012;31(33):3741–53. https://doi.org/10.1038/onc.2011.540.
Article
CAS
PubMed
Google Scholar
Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334–42. https://doi.org/10.1111/cas.12488.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, Osaki A. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer. 2016;114(11):1212–8. https://doi.org/10.1038/bjc.2016.122.
Article
CAS
PubMed
PubMed Central
Google Scholar
Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, Littlefield BA. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71(2):496–505. https://doi.org/10.1158/0008-5472.CAN-10-1874.
Article
CAS
PubMed
Google Scholar
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, investigators E. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23. https://doi.org/10.1016/s0140-6736(11)60070-6.
Article
CAS
PubMed
Google Scholar
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. https://doi.org/10.1200/JCO.2013.52.4892.
Article
CAS
PubMed
PubMed Central
Google Scholar
Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553–61. https://doi.org/10.1007/s10549-014-3144-y.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kotake T, Kikawa Y, Takahara S, Tsuyuki S, Yoshi-bayashi H, Suzuki E, Moriguchi Y, Yamashiro H, Yamagami K, Suwa H, Okuno T, Okamura T, Hashimoto T, Kato H, Tsuji A, Toi M. Impact of Eribulin Monotherapy on post-progression survival in patients with HER2-negative advanced or metastatic breast Cancer. Int J Cancer Clin Res. 2016;3(4):061.
Article
Google Scholar
Garrone O, Montemurro F, Saggia C, La Verde N, Vandone AM, Airoldi M, De Conciliis E, Donadio M, Lucio F, Polimeni MA, Oletti MV, Giacobino A, Merlano MC. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. Springerplus. 2016;5:59. https://doi.org/10.1186/s40064-016-1700-0.
Article
CAS
PubMed
PubMed Central
Google Scholar
Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA. “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res. 2015;17(1):150. https://doi.org/10.1186/s13058-015-0657-1.
Article
CAS
PubMed
PubMed Central
Google Scholar
O'Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, Song J, Vahdat L. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. Springerplus. 2015;4:532. https://doi.org/10.1186/s40064-015-1322-y.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cashman J, Wright J, Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer. 2010;18(5):651–5. https://doi.org/10.1007/s00520-010-0813-1.
Article
PubMed
Google Scholar
Muss HB. Coming of age: breast cancer in seniors. Oncologist. 2011;16(Suppl 1):79–87. https://doi.org/10.1634/theoncologist.2011-S1-79.
Article
PubMed
Google Scholar
Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ. Novel second generation analogs of eribulin. Part III: blood-brain barrier permeability and in vivo activity in a brain tumor model. Bioorg Med Chem Lett. 2011;21(6):1639–43. https://doi.org/10.1016/j.bmcl.2011.01.096.
Article
CAS
PubMed
Google Scholar
Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, Guardascione M, Fontanella C, Fasola G, Puglisi F. Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis. 2013;30(8):951–6. https://doi.org/10.1007/s10585-013-9594-5.
Article
CAS
PubMed
Google Scholar
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, Version 3.2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 10 Jan 2018.
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group EGW. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11–9. https://doi.org/10.1093/annonc/mds232.
Article
PubMed
Google Scholar
Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS, Force E-MT. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174–81. https://doi.org/10.1093/jnci/djp235.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rossi S, Cassano A, Strippoli A, Schinzari G, D'Argento E, Basso M, Barone C. Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies. Drugs Context. 2017;6:212506. https://doi.org/10.7573/dic.212506.
Article
PubMed
PubMed Central
Google Scholar
Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O'Shaughnessy J. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist. 2014;19(4):318–27. https://doi.org/10.1634/theoncologist.2013-0282.
Article
CAS
PubMed
PubMed Central
Google Scholar
de Nonneville A, Sabatier R, Goncalves A, Extra JM, Tarpin C, Launay S, Tassy L, Viens P, Rousseau F. Safety and efficacy of eribulin for “real-world” older patients with metastatic breast cancer. J Geriatr Oncol. 2018;9(3):281–3. https://doi.org/10.1016/j.jgo.2017.11.003.
Article
PubMed
Google Scholar
Bao PP, Cai H, Peng P, Gu K, Su Y, Shu XO, Zheng Y. Body mass index and weight change in relation to triple-negative breast cancer survival. Cancer Causes Control. 2016;27(2):229–36. https://doi.org/10.1007/s10552-015-0700-7.
Article
PubMed
Google Scholar
Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. https://doi.org/10.1093/annonc/mdu042.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Grassadonia A, Michelotti A, Landucci E, Perracchio L, Pescarmona E, Di Filippo F, Giordano A, Maugeri-Sacca M, Vici P. Body mass index and treatment outcomes in metastatic breast Cancer patients treated with Eribulin. J Cell Physiol. 2016;231(5):986–91. https://doi.org/10.1002/jcp.25213.
Article
CAS
PubMed
Google Scholar
Chang AY, Ying XX. Brain metastases from breast Cancer and response to treatment with Eribulin: a case series. Breast Cancer (Auckl). 2015;9:19–24. https://doi.org/10.4137/BCBCR.S21176.
Article
CAS
Google Scholar
Nieder C, Aandahl G, Dalhaug A. A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Rep Oncol Med. 2012;2012:537183. https://doi.org/10.1155/2012/537183.
Article
PubMed
PubMed Central
Google Scholar
Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A. Activity of Eribulin Mesylate in brain metastasis from breast Cancer: a stone in a pond? Oncology. 2018;94(Suppl 1):29–33. https://doi.org/10.1159/000489066.
Article
CAS
PubMed
PubMed Central
Google Scholar
Matsuoka H, Tsurutani J, Tanizaki J, Iwasa T, Komoike Y, Koyama A, Nakagawa K. Regression of brain metastases from breast cancer with eribulin: a case report. BMC Res Notes. 2013;6:541. https://doi.org/10.1186/1756-0500-6-541.
Article
PubMed
PubMed Central
Google Scholar
Kashiwagi S, Tsujio G, Asano Y, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. J Transl Med. 2018;16(1):54. https://doi.org/10.1186/s12967-018-1443-5.
Article
CAS
PubMed
PubMed Central
Google Scholar